The Multiple Sleep Latency Test (MSLT) and the Maintenance of Wakefulness Test (MWT) are daytime tests that quantify the propensity to fall asleep (MSLT) or the ability to stay awake (MWT). Both follow standardized protocols. The MSLT is essential for diagnosing narcolepsy and idiopathic hypersomnia and is among the most specific tests in clinical neurophysiology. The MWT assesses safety-critical wakefulness (e.g., commercial driving, airline pilots). This page covers the MSLT and MWT protocols, normal and diagnostic findings, and the integration with overnight PSG.

Multiple Sleep Latency Test (MSLT)

Indications

  • Evaluation of excessive daytime sleepiness (EDS).
  • Diagnosis of narcolepsy (type 1 and type 2).
  • Diagnosis of idiopathic hypersomnia.
  • Quantification of severity of sleepiness.

Protocol (AASM 2021)

  • Performed the day after a full overnight PSG that confirms ≥6 hours of total sleep and rules out other sleep disorders.
  • 5 nap opportunities at 2-hour intervals (start-to-start), not back-to-back.
  • First nap begins 1.5 to 3 hours after the overnight PSG ends.
  • For each nap: patient placed in bed in a dark, quiet room, instructed to try to sleep.
  • Nap trial ends:
    • After 20 minutes if no sleep occurs; OR
    • 15 minutes after the first epoch of sleep (allowing time to capture SOREMPs).
  • Patient remains awake and out of bed between naps; light meals and bathroom breaks allowed.
  • Pediatric MSLT protocols differ (different normative ranges, sometimes 4 naps) and should not be assumed identical to the adult protocol.

Preparation

  • Patient should have slept ≥6 hours night before.
  • Caffeine restricted day of test.
  • Stimulants and REM-suppressing medications (SSRIs, SNRIs, TCAs) usually held for 2 weeks if possible.
  • Sleep diary 1–2 weeks beforehand confirms adequate sleep.

Measurements

  • Sleep latency: time from lights out to first sleep epoch.
  • Averaged across all 5 naps.
  • SOREMP (Sleep Onset REM Period): REM occurring within 15 minutes of sleep onset; counted if present in any nap.

Diagnostic Criteria

Narcolepsy Type 1 (with cataplexy)

  • EDS.
  • Cataplexy (typical).
  • MSLT: mean sleep latency ≤8 minutes AND ≥2 SOREMPs (including any captured on overnight PSG).
  • OR documented low CSF orexin (hypocretin-1) <110 pg/mL.

Narcolepsy Type 2 (without cataplexy)

  • EDS.
  • No cataplexy.
  • MSLT: mean sleep latency ≤8 minutes AND ≥2 SOREMPs.
  • Normal CSF orexin.
  • Less common than type 1.

Idiopathic Hypersomnia

  • EDS without cataplexy.
  • MSLT: mean sleep latency ≤8 minutes.
  • Either ≤1 SOREMP OR no SOREMPs.
  • Some patients may have monosymptomatic idiopathic hypersomnia (sleep latency >8 min but pathologic prolonged sleep).

Normal MSLT

  • Mean sleep latency typically >15 minutes in healthy adults without sleep disorders.
  • <5 minutes is severely pathologic.
  • 5–10 minutes is moderate.

MSLT Pitfalls

False Positives

  • Severe untreated OSA may show short latencies and SOREMPs.
  • Shift work or sleep deprivation.
  • Medication effects (REM-suppressing meds altering REM rebound).
  • Recent sleep deprivation.

False Negatives

  • Stimulant use day of test.
  • Caffeine.
  • Anxiety preventing sleep onset.
  • Sleep diary not adequately confirmed.

Special Considerations

  • SOREMPs on overnight PSG count toward MSLT requirement.
  • Shift work and inadequate sleep can lead to misdiagnosis.
  • Sleep diary essential.
  • Discontinuation of REM-suppressing medication 2 weeks recommended (sometimes longer for fluoxetine).

Maintenance of Wakefulness Test (MWT)

Indications

  • Quantify ability to stay awake when motivated.
  • Safety-critical occupations: commercial drivers, airline pilots, train conductors.
  • Follow-up assessment after treatment of narcolepsy.
  • Differentiating EDS from depression or boredom-related sleepiness.

Protocol

  • 4 nap opportunities, each 40 minutes, with 2-hour intervals.
  • Patient instructed to STAY AWAKE.
  • Sitting upright in dimly lit room.
  • Each session ends at 40 minutes (if still awake) or at first sleep epoch.

Measurements

  • Sleep latency: time from start of session to first sleep epoch.
  • Averaged across 4 sessions.
  • Normal: ≥30 minutes; lower scores indicate impaired alertness.

Interpretation

  • ≥40 minutes: full wakefulness maintained.
  • 20–40 minutes: borderline.
  • <10 minutes: severely impaired alertness; safety concern.
  • Lower scores correlate with driving impairment.
  • Used to monitor treatment response in narcolepsy.

Diagnostic Workup for EDS

Initial Assessment

  • Sleep history.
  • Sleep diary 1–2 weeks.
  • Epworth Sleepiness Scale.
  • Stanford Sleepiness Scale.

Differential

  • Insufficient sleep syndrome (most common).
  • Obstructive sleep apnea (very common).
  • Narcolepsy type 1 or 2.
  • Idiopathic hypersomnia.
  • Periodic limb movements with disrupted sleep.
  • Circadian rhythm disorders.
  • Medications (sedatives, antihistamines, antidepressants).
  • Depression.
  • Kleine-Levin syndrome (rare).

Diagnostic Tests

  • PSG: exclude OSA and other primary sleep disorders.
  • MSLT: quantify daytime sleepiness, detect narcolepsy.
  • CSF orexin: confirm narcolepsy type 1 if available.
  • HLA typing: HLA-DQB1*06:02 in nearly all narcolepsy type 1.
  • Imaging: rule out hypothalamic lesion.

Narcolepsy Pathophysiology

  • Loss of hypocretin-producing neurons in lateral hypothalamus.
  • Autoimmune mechanism suggested.
  • HLA-DQB1*06:02 in >95% of narcolepsy type 1.
  • Associated with H1N1 (Pandemrix vaccine and natural infection in 2009-2010).
  • Classic tetrad: EDS, cataplexy, sleep paralysis, hypnagogic hallucinations.

Cataplexy

  • Sudden loss of muscle tone triggered by emotion (laughter, surprise).
  • Partial (face, jaw) to complete (collapse) episodes.
  • Pathognomonic for narcolepsy type 1.
  • Often misdiagnosed initially.

Treatment of Narcolepsy

EDS Management

  • Modafinil, armodafinil: wakefulness-promoting; first-line.
  • Methylphenidate, amphetamines: stimulants; effective but more side effects.
  • Sodium oxybate: GHB; effective for EDS and cataplexy.
  • Pitolisant: H3 receptor antagonist; both EDS and cataplexy.
  • Solriamfetol: dopamine/NE reuptake inhibitor; EDS in narcolepsy or OSA.

Cataplexy Management

  • Sodium oxybate: most effective.
  • SSRIs, SNRIs (venlafaxine, fluoxetine): REM-suppressing.
  • TCAs: protriptyline.
  • Pitolisant: cataplexy effect documented.

Sleep Hygiene

  • Regular schedule, scheduled naps, avoid alcohol, manage sleep deprivation.

Idiopathic Hypersomnia

Clinical

  • Chronic EDS without cataplexy.
  • Long sleep time (often >10 hours/night).
  • Sleep inertia (difficulty waking, feeling groggy).
  • Less responsive to stimulants than narcolepsy.

Diagnostic

  • MSLT: short latency, no or 1 SOREMP.
  • Some have normal MSLT but pathologic prolonged sleep.

Treatment

  • Modafinil, methylphenidate, amphetamines.
  • Lower doses than narcolepsy often.
  • Xywav (low-sodium oxybate): FDA-approved 2021.

Practical Issues

Drug Effects on MSLT

  • SSRIs, SNRIs: suppress REM; may reduce SOREMPs and falsely negative MSLT.
  • Stimulants: can prevent sleep; falsely negative MSLT.
  • Caffeine: similar.
  • Sleep deprivation in days before testing: can cause false-positive findings.

Reliability

  • MSLT/MWT reliability depends on patient cooperation and adherence to preparation.
  • Sleep diary documentation often essential for confidence.
  • Borderline cases may require repeat testing.

🔍 Did You Know?

The HLA-DQB1*06:02 allele is present in >95% of narcolepsy type 1 patients, making it one of the strongest HLA-disease associations in human medicine — stronger than any individual HLA-disease association in autoimmune disease. However, the same allele is present in about 15–25% of the general population, so it’s necessary but not sufficient for diagnosis. The clinical implication is that HLA testing has high negative predictive value: a negative HLA-DQB1*06:02 essentially excludes narcolepsy type 1 (very few exceptions reported). But a positive result doesn’t establish diagnosis — many people carry it without ever developing narcolepsy. Combined with the autoimmune hypothesis (loss of hypocretin-producing hypothalamic neurons), the 2009 H1N1 association (Pandemrix vaccine and natural infection both linked to narcolepsy onset), and the consistent finding of low CSF orexin in type 1, the picture is of an HLA-restricted autoimmune destruction of hypothalamic hypocretin neurons triggered by specific environmental factors. For practicing neurologists, the diagnostic workup for suspected narcolepsy type 1 should include: PSG + MSLT (typical short latency + ≥2 SOREMPs), and either HLA-DQB1*06:02 typing (highly sensitive but not specific) or CSF orexin measurement (most specific test). The lesson generalizes: genetic association studies have transformed our understanding of “idiopathic” neurologic syndromes, and clinical diagnosis increasingly uses HLA and other genetic markers alongside traditional phenotypic criteria.

Pitfalls and Pearls

  • MSLT: 5 naps with 2-hr intervals; measures sleep latency and SOREMPs.
  • Narcolepsy type 1: mean sleep latency ≤8 min + ≥2 SOREMPs + cataplexy OR low CSF orexin.
  • Narcolepsy type 2: same MSLT findings but no cataplexy and normal orexin.
  • Idiopathic hypersomnia: short latency but ≤1 SOREMP.
  • Normal mean sleep latency: typically >15 min.
  • SOREMPs on overnight PSG count: toward MSLT requirement.
  • REM-suppressing meds: hold 2 weeks before MSLT.
  • Sleep diary: confirms adequate prior sleep; essential.
  • OSA mimicker: severe untreated OSA can produce short latencies and SOREMPs.
  • HLA-DQB1*06:02: in >95% of narcolepsy type 1; negative result excludes.
  • CSF orexin <110: highly specific for narcolepsy type 1.
  • Cataplexy: pathognomonic for narcolepsy type 1; emotional trigger.
  • MWT: tests ability to stay awake; 4 sessions of 40 min; safety-critical occupations.
  • MWT normal: ≥30 min; <10 min severely impaired.
  • MWT: used for narcolepsy treatment monitoring.
  • EDS differential: insufficient sleep, OSA, narcolepsy, idiopathic hypersomnia, circadian disorders, meds.
  • Treatment: modafinil/armodafinil first-line; sodium oxybate, pitolisant, solriamfetol.

References

  1. Krahn LE, Arand DL, Avidan AY, et al. Recommended protocols for the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. J Clin Sleep Med. 2021;17(12):2489-2498.
  2. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Sleep. 2005;28(1):113-121.
  3. Krahn LE, Hershner S, Loeding LD, et al. Quality measures for the care of patients with narcolepsy. J Clin Sleep Med. 2015;11(3):335-355.
  4. Mignot E. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739-752.
  5. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. American Academy of Sleep Medicine; 2014.
  6. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662.
  7. Sarkanen TO, Alakuijala AP, Dauvilliers Y, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev. 2018;38:177-186.